Evommune, Inc. (EVMN) - Total Liabilities
Based on the latest financial reports, Evommune, Inc. (EVMN) has total liabilities worth $19.38 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evommune, Inc. - Total Liabilities Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Evommune, Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Evommune, Inc. Competitors by Total Liabilities
The table below lists competitors of Evommune, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Jinma Entertainment Corp Ltd
SHE:300756
|
China | CN¥892.15 Million |
|
Xuchang Yuandong Drive Shaft Co Ltd
SHE:002406
|
China | CN¥836.18 Million |
|
Fujian SuperTech Advanced Material Co Ltd
SHG:688398
|
China | CN¥945.69 Million |
|
Cancom SE
F:COK
|
Germany | €775.02 Million |
|
Navient Corp
NASDAQ:NAVI
|
USA | $46.28 Billion |
|
Eastman Kodak Co
NYSE:KODK
|
USA | $1.21 Billion |
|
Huayi Compressor Co Ltd
SHE:000404
|
China | CN¥9.28 Billion |
|
Bassac
PA:BASS
|
France | €1.49 Billion |
Liability Composition Analysis (2023–2025)
This chart breaks down Evommune, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVMN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evommune, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evommune, Inc. (2023–2025)
The table below shows the annual total liabilities of Evommune, Inc. from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.38 Million | -91.20% |
| 2024-12-31 | $220.29 Million | +37.71% |
| 2023-12-31 | $159.96 Million | -- |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more